UnifiedACB

Medication evidence profile

Pimozide

Ask about Pimozide

Clinical overview

Pimozide has public medication-list entries in Yamada-ABS 2023, BAAS 2019, GABS 2018, KABS 2020 open validation supplement, and CALS 2022 Table 4. These are 5 separate source versions, each with its own evidence and definitions.

Source-specific scores

SourceScore
JARSNot listed
Yamada-ABS0
BAAS2
Swe-ABSNot listed
GABS2
KABS2
CALS2

How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.

How to interpret the evidence

5 of 7 public source versions contain an explicit medication-list entry for pimozide.

The recorded values differ across the source rows for pimozide. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.

Yamada-ABS 2023 explicitly records zero. Those recorded zeros remain different from a missing entry.

Source labels and provenance · 5 observations
  1. Yamada Pharmacological Anticholinergic Burden Scale 2023

    Source label: pimozide. Published value: 0.
    Source version: YAMADA-ABS-2023
    Source location: GGI-23-558-s002.docx Table S1 row 12 (Antipsychotics)
    Observation: YAMADA_ABS_2023_R0159; rating state: published_zero.

  2. Brazilian Anticholinergic Activity Scale 2019

    Source label: Pimozide. Published value: 2.
    Source version: BAAS-2019
    Source location: RC4 source recovery; recovery_scope=primary_table_complete
    Observation: BAAS_2019_R0056; rating state: published_rating.

  3. German Anticholinergic Burden Score 2018

    Source label: Pimozide. Published value: 2.
    Source version: GABS-2018
    Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
    Observation: GABS_2018_R0118; rating state: published_rating.

  4. KABS 2019 scale - 2020 open validation supplement

    Source label: Pimozide. Published value: 2.
    Source version: KABS-2020-validation-supplement
    Source location: Additional file 1; category Antipsychotics; table row 41
    Observation: KABS2020_SUPP_0186; rating state: published_validation_supplement_rating.

  5. CALS 2022 - primary final Table 4

    Source label: Pimozide. Published value: 2.
    Source version: CALS-2022-primary-table4
    Source location: Table 4; literal capture row 131; displayed table row 19; displayed column 5
    Observation: CALS2022_T4_0131; rating state: published_final_table_rating.

What this page does not establish

  • No medication-list entry is available here from JARS 2025 and Swe-ABS 2023. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
  • No route inference unless present in the source label.
  • These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.

References

  1. Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
  2. Nery RT, Reis AMM. Development of a Brazilian anticholinergic activity drug scale. Einstein (Sao Paulo). 2019;17(2):eAO4435. doi:10.31744/einstein_journal/2019AO4435. Open source
  3. Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
  4. Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
  5. Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source

Ask a follow-up

Go to your medication comparison · How UnifiedACB handles disagreement

Ask about this medication

Medication context: Pimozide

Ask about this medication
Show Pimozide across all available scalesWhy do the scales differ for Pimozide?Show the evidence for PimozideCompare Pimozide with another medication